Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses

US10273237B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Chunjian Liu · Pennington, US
• James Lin · Lawrenceville, US
• Ryan M. Moslin · Princeton, US
• David S. Weinstein · Plainsboro, US
• John S. Tokarski · Princeton, US

Key dates

• Filing date: Dec 10, 2014
• Grant date: Apr 30, 2019
• Expiry date: Dec 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.